Segment Reporting – Pharmaceuticals

 

XLS

 

 

 

 

 

 

 

 

Merck Serono

Consumer Health Care

Pharmaceuticals

EUR million

Q1
2011

Q1
2010

Q1
2011

Q1
2010

Q1
2011

Q1
2010

*

Reporting period ending on March 31, 2011. The previous year’s figures as of December 31, 2010.

Sales

1,344.9

1,336.3

116.2

106.9

1,461.2

1,443.2

Royalty, license and commission income

82.3

70.5

0.3

0.7

82.6

71.2

Total revenues

1,427.2

1,406.8

116.6

107.6

1,543.8

1,514.4

Gross margin

1,221.6

1,186.5

82.1

72.8

1,303.7

1,259.4

Marketing and selling expenses

–351.7

–322.2

–60.6

–56.8

–412.3

–379.0

Royalty, license and commission expenses

–106.3

–116.9

–0.4

–0.2

–106.7

–117.0

Administration expenses

–62.5

–62.3

–6.0

–5.9

–68.5

–68.3

Other operating expenses and income

–48.0

–65.1

–1.5

–2.6

–49.5

–67.7

Research and development

–305.6

–304.4

–4.8

–4.8

–310.5

–309.3

Operating result

148.4

178.0

7.7

1.5

156.1

179.5

Exceptional items

1.0

1.0

Earnings before interest and tax (EBIT)

149.4

178.0

7.7

1.5

157.1

179.5

Net operating assets*

9,962.2

10,359.7

306.8

310.8

10,269.0

10,670.5

Segment liabilities*

–1,229.0

–1,268.9

–79.9

–86.4

–1,308.8

–1,355.3

Capital spending on property, plant and equipment

44.8

46.0

0.6

1.4

45.5

47.4

Investments in intangible assets

5.1

11.5

0.1

0.3

5.2

11.8

Depreciation and amortization

–199.4

–181.8

–2.6

–2.8

–202.1

–184.5

Impairment losses

–50.4

–17.2

–50.4

–17.2

Net cash flows from operating activities

340.8

246.1

13.8

–1.2

354.5

244.9

Net cash flows from investing activities

197.4

–54.7

–0.8

–1.3

196.7

–56.0

Free cash flow

538.2

191.4

13.0

–2.5

551.2

188.9

Underlying free cash flow

273.1

191.4

13.0

–2.5

286.1

188.9

FCR in %

19.1

13.6

11.2

–2.3

18.5

12.5

ROS in %

10.4

12.7

6.6

1.4

10.1

11.9